

# Ocular Hypertension: Drug Development Pipeline Study, H1 2018

<https://marketpublishers.com/r/OA851B78D8EEN.html>

Date: March 2018

Pages: 61

Price: US\$ 895.00 (Single User License)

ID: OA851B78D8EEN

## Abstracts

Ocular Hypertension pipeline comprises of 27 drugs under development as of March 2018. Of these, 2 drugs are in Phase 1 and 13 drugs in phase 2 and 6 drugs in Phase 3. Further, 5 drugs remain in Pre-clinical stage. One drug is in pre-registration stage.

20 companies are developing the pipeline for Ocular Hypertension. Of this, Santen Pharmaceutical Co Ltd and NicOx SA have largest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Prostaglandin E EP2 receptor agonist.

Ocular Hypertension is a condition where, InterOcular Pressure (IOP) is more than the maximum limit of 21 mmHg in one or both the eyes with older population largely affected by the condition. The pressure increase is observed without any observed optic nerve damage or vision loss.

If untreated, the disease can evolve into glaucoma and can also lead to permanent vision loss. In specific, African and Caribbean population is more susceptible to Ocular Hypertension compared to Europeans. Further, the condition is more common among nearsighted and diabetic patients.

The pressure increase is observed typically because of aqueous humor or drainage problems, which results in fluid buildup, resulting in elevated eye pressure.

The most comprehensive pipeline review "Ocular Hypertension- Drug Development Pipeline Study" provides in-depth analysis and update information on Ocular Hypertension pipeline drugs. Current status of all the drugs in the Ocular Hypertension pipeline is provided in the research work.

The report provides detailed analysis of Ocular Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Ocular Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Ocular Hypertension industry.

**Scope:**

- All latest industry developments and their impact on projects and companies
- Complete overview of global Ocular Hypertension therapy options and treatments
- The pipeline study reviews drug details for Ocular Hypertension by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- Mergers, Acquisitions, licensing, co-development and project acquisition news for Ocular Hypertension market
- Ocular Hypertension drugs being developed in combination with other drugs are also detailed
- Company wise drugs listed with their current status, partners and news updates

## Contents

### **1 TABLE OF CONTENTS**

1.1 LIST OF FIGURES

1.2 LIST OF TABLES

### **2 EXECUTIVE SUMMARY**

2.1 DISEASE OVERVIEW

2.2 PIPELINE SNAPSHOT

2.3 PIPELINE DRUGS BY PHASE

2.4 PIPELINE DRUGS BY COMPANY

2.5 PIPELINE DRUGS BY MECHANISM OF ACTION

### **3 OCULAR HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS**

3.1 AERIE PHARMACEUTICALS, INC PIPELINE, H1 2018

3.2 ALCON LABORATORIES INC PIPELINE, H1 2018

3.3 ALLERGAN PLC PIPELINE, H1 2018

3.4 CAN-FITE BIOPHARMA LTD PIPELINE, H1 2018

3.5 D. WESTERN THERAPEUTICS INSTITUTE INC PIPELINE, H1 2018

3.6 ENVISIA THERAPEUTICS INC PIPELINE, H1 2018

3.7 F. HOFFMANN-LA ROCHE LTD PIPELINE, H1 2018

3.8 IRONWOOD PHARMACEUTICALS INC PIPELINE, H1 2018

3.9 LABORATORIOS SOPHIA S.A. DE C.V PIPELINE, H1 2018

3.10 MATI THERAPEUTICS INC PIPELINE, H1 2018

3.11 NEURIM PHARMACEUTICALS LTD PIPELINE, H1 2018

3.12 NICOX SA PIPELINE, H1 2018

3.13 OCULAR THERAPEUTIX INC PIPELINE, H1 2018

3.14 PEREGRINE OPHTHALMIC PIPELINE, H1 2018

3.15 SANTEN PHARMACEUTICAL CO LTD PIPELINE, H1 2018

3.16 SENJU PHARMACEUTICAL CO.,LTD PIPELINE, H1 2018

3.17 SHIRE PLC PIPELINE, H1 2018

3.18 SYLENTIS SAU PIPELINE, H1 2018

3.19 TAEJOON PHARMACEUTICAL CO., LTD. PIPELINE, H1 2018

3.20 VISCI LTD. PIPELINE, H1 2018

### **4 OCULAR HYPERTENSION DRUG SNAPSHOTS**

#### 4.1 ROCLATAN DRUG DETAILS

- 4.1.1 Snapshot-
- 4.1.2 Drug Overview-
- 4.1.3 Mechanism of Action-
- 4.1.4 Current Status-
- 4.1.5 Phase 3 Details
- 4.1.6 Trial details include-

#### 4.2 MGV354 DRUG DETAILS

- 4.2.1 Snapshot-
- 4.2.2 Drug Overview
- 4.2.3 Mechanism of Action
- 4.2.4 Current Status

#### 4.3 BIMATOPROST OCULAR INSERT

- 4.3.1 Snapshot-
- 4.3.2 Drug overview
- 4.3.3 Mechanism of Action
- 4.3.4 Phase 1/ 2 trial details

#### 4.4 CF 101 DRUG DETAILS

- 4.4.1 Snapshot-
- 4.4.2 Drug Overview
- 4.4.3 Mechanism of Action
- 4.4.4 Current Status
- 4.4.5 Trial Details

#### 4.5 WP-1303 DRUG DETAILS

- 4.5.1 Snapshot-
- 4.5.2 Drug Overview
- 4.5.3 Mechanism of Action
- 4.5.4 Current Status
- 4.5.5 Trial Details

#### 4.6 ENV515 DRUG DETAILS

- 4.6.1 Snapshot-
- 4.6.2 Drug Overview
- 4.6.3 Mechanism of Action
- 4.6.4 Current Status
- 4.6.5 Trial Details

#### 4.7 RG 7945- DRUG DETAILS

- 4.7.1 Snapshot-
- 4.7.2 Drug Overview

- 4.7.3 Mechanism of Action
- 4.7.4 Current Status
- 4.7.5 Phase 1 trial details
- 4.8 IWP 953 DRUG DETAILS
  - 4.8.1 Snapshot-
  - 4.8.2 Drug Overview
  - 4.8.3 Mechanism of Action
  - 4.8.4 Current Status
  - 4.8.5 Trial details
- 4.9 SOPH067 DRUG DETAILS
  - 4.9.1 Snapshot-
  - 4.9.2 Drug Overview
  - 4.9.3 Mechanism of Action
  - 4.9.4 Current Status
  - 4.9.5 Phase 3 Trial details
- 4.10 PRO-122 DRUG DETAILS
  - 4.10.1 Snapshot-
  - 4.10.2 Drug Overview
  - 4.10.3 Mechanism of Action
  - 4.10.4 Current Status
  - 4.10.5 Trial details
- 4.11 PIROMELATINE DRUG DETAILS
  - 4.11.1 Snapshot-
  - 4.11.2 Drug Overview
  - 4.11.3 Mechanism of Action
  - 4.11.4 Current Status
  - 4.11.5 Trial details
- 4.12 NCX 470 DRUG DETAILS
  - 4.12.1 Snapshot-
  - 4.12.2 Drug Overview
  - 4.12.3 Mechanism of Action
  - 4.12.4 Current Status
  - 4.12.5 Trial Details
- 4.13 NCX 667 DRUG DETAILS
  - 4.13.1 Snapshot-
  - 4.13.2 Drug Overview
  - 4.13.3 Mechanism of Action
  - 4.13.4 Current Status
  - 4.13.5 Trial details

#### 4.14 NCX 1653 DRUG DETAILS

- 4.14.1 Snapshot-
- 4.14.2 Drug Overview
- 4.14.3 Mechanism of Action
- 4.14.4 Current Status

#### 4.15 OTX-TP DRUG DETAILS

- 4.15.1 Snapshot-
- 4.15.2 Drug Overview
- 4.15.3 Mechanism of Action
- 4.15.4 Current Status
- 4.15.5 Trial details

#### 4.16 OTX-TIC DRUG DETAILS

- 4.16.1 Snapshot-
- 4.16.2 Drug Overview
- 4.16.3 Mechanism of Action
- 4.16.4 Current Status
- 4.16.5 Trial Details

#### 4.17 DE-117 DRUG DETAILS

- 4.17.1 Snapshot-
- 4.17.2 Drug Overview
- 4.17.3 Mechanism of Action
- 4.17.4 Current Status
- 4.17.5 Trial details

#### 4.18 DE 126 DRUG DETAILS

- 4.18.1 Snapshot-
- 4.18.2 Drug Overview
- 4.18.3 Mechanism of Action
- 4.18.4 Current Status
- 4.18.5 Trial details

#### 4.19 DE-130A DRUG DETAILS

- 4.19.1 Snapshot-
- 4.19.2 Drug Overview
- 4.19.3 Mechanism of Action
- 4.19.4 Current Status

#### 4.20 Y-39983 DRUG DETAILS

- 4.20.1 Snapshot-
- 4.20.2 Drug Overview
- 4.20.3 Mechanism of Action
- 4.20.4 Current Status

- 4.20.5 Trial details
- 4.21 SJP 0135 DRUG DETAILS
  - 4.21.1 Snapshot-
  - 4.21.2 Drug Overview
  - 4.21.3 Mechanism of Action
  - 4.21.4 Current Status
  - 4.21.5 Trial details
- 4.22 SHP 639 DRUG DETAILS
  - 4.22.1 Snapshot-
  - 4.22.2 Drug Overview
  - 4.22.3 Mechanism of Action
  - 4.22.4 Current Status
  - 4.22.5 Trial details
- 4.23 BAMOSIRAN DRUG DETAILS
  - 4.23.1 Snapshot-
  - 4.23.2 Drug Overview
  - 4.23.3 Mechanism of Action
  - 4.23.4 Current Status
  - 4.23.5 Trial details
- 4.24 LATANOPROST-PPDS DRUG DETAILS
  - 4.24.1 Snapshot-
  - 4.24.2 Drug Overview
  - 4.24.3 Mechanism of Action
  - 4.24.4 Current Status
  - 4.24.5 Trial Details
- 4.25 VS 101 DRUG DETAILS
  - 4.25.1 Snapshot-
  - 4.25.2 Drug Overview
  - 4.25.3 Mechanism of Action
  - 4.25.4 Current Status
- 4.26 LIPOSOMAL LATANOPROST DRUG DETAILS
  - 4.26.1 Snapshot-
  - 4.26.2 Drug Overview
  - 4.26.3 Mechanism of Action
  - 4.26.4 Current Status
  - 4.26.5 Trial details
- 4.27 TJO 002 DRUG DETAILS
  - 4.27.1 Snapshot-
  - 4.27.2 Drug Overview

4.27.3 Current status

4.27.4 Trial details

## **5 RECENT DEVELOPMENTS IN OCULAR HYPERTENSION PIPELINE**

5.1 FDA APPROVES LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION

0.024% - NOVEMBER 2017

5.2 DAILY USE OF STEROID DROPS INCREASES RISK FOR OCULAR  
HYPERTENSION - JULY 2017

5.3 NICOX PROVIDES CLINICAL AND REGULATORY UPDATE FOR NCX 470 FOR  
IOP LOWERING- JANUARY 2017

## **6 APPENDIX**

6.1 ABOUT VPA RESEARCH

6.2 SOURCES AND RESEARCH METHODOLOGY



## List Of Figures

### LIST OF FIGURES

Figure 1: Ocular Hypertension Pipeline by Phase, H1- 2018

Figure 2: Ocular Hypertension Pipeline by Companies, H1- 2018

Figure 3: Company wise Pipeline Drug Phases, H1- 2018

Figure 4: Ocular Hypertension Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018

## List Of Tables

### LIST OF TABLES

- Table 1: Ocular Hypertension Pipeline by Phase, H1- 2018
- Table 2: Ocular Hypertension Pipeline by Companies, H1- 2018
- Table 3: Ocular Hypertension Pipeline by Mechanism of Action, H1- 2018
- Table 4: Aerie Pharmaceuticals, Inc - Ocular Hypertension Pipeline, H1- 2018
- Table 5: Alcon Laboratories Inc - Ocular Hypertension Pipeline, H1- 2018
- Table 6: Allergan Plc - Ocular Hypertension Pipeline, H1- 2018
- Table 7: Can-Fite BioPharma Ltd - Ocular Hypertension Pipeline, H1- 2018
- Table 8: D. Western Therapeutics Institute Inc - Ocular Hypertension Pipeline, H1- 2018
- Table 9: Envisia Therapeutics Inc - Ocular Hypertension Pipeline, H1- 2018
- Table 10: F. Hoffmann-La Roche Ltd- Ocular Hypertension Pipeline, H1- 2018
- Table 11: Ironwood Pharmaceuticals Inc- Ocular Hypertension Pipeline, H1- 2018
- Table 12: Laboratorios Sophia S.A. De C.V- Ocular Hypertension Pipeline, H1- 2018
- Table 13: Mati Therapeutics Inc - Ocular Hypertension Pipeline, H1- 2018
- Table 14: Neurim Pharmaceuticals Ltd - Ocular Hypertension Pipeline, H1- 2018
- Table 15: NicOx SA - Ocular Hypertension Pipeline, H1- 2018
- Table 16: Ocular Therapeutix Inc - Ocular Hypertension Pipeline, H1- 2018
- Table 17: Peregrine Ophthalmic - Ocular Hypertension Pipeline, H1- 2018
- Table 18: Santen Pharmaceutical Co Ltd - Ocular Hypertension Pipeline, H1- 2018
- Table 19: SENJU Pharmaceutical Co.,Ltd - Ocular Hypertension Pipeline, H1- 2018
- Table 20: Shire Plc - Ocular Hypertension Pipeline, H1- 2018
- Table 21: Sylentis SAU - Ocular Hypertension Pipeline, H1- 2018
- Table 22: Taejoon Pharmaceutical Co., Ltd.- Ocular Hypertension Pipeline, H1- 2018
- Table 23: ViSci Ltd. - Ocular Hypertension Pipeline, H1- 2018

## I would like to order

Product name: Ocular Hypertension: Drug Development Pipeline Study, H1 2018

Product link: <https://marketpublishers.com/r/OA851B78D8EEN.html>

Price: US\$ 895.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OA851B78D8EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970